Global Biopsy Forceps, Polypectomy Snares and EUS Needles Market Size By Type (Biopsy Forceps, Polypectomy Snare), By Application (Stomach, Gut), By Region, And Segment Forecasts, 2023 to 2032

lobal Biopsy Forceps, Polypectomy Snares and EUS Needles Market

The Global Biopsy Forceps, Polypectomy Snares and EUS Needles Market was valued at USD 1.2 billion in 2023 and is projected to surpass USD 2.1 billion by 2031, growing at a CAGR of 7.2% during the forecast period of 2023–2031. The market is driven by the increasing incidence of gastrointestinal (GI) diseases, rising demand for minimally invasive diagnostic and therapeutic procedures, and advancements in endoscopic technologies. These instruments are essential tools in endoscopic procedures for tissue sampling, polyp removal, and ultrasound-guided interventions, thus witnessing significant uptake in clinical settings worldwide.

Drivers:

Rising Prevalence of Gastrointestinal Disorders:

An increasing number of patients diagnosed with GI conditions such as colorectal cancer, inflammatory bowel disease, and polyps has driven the adoption of diagnostic and therapeutic endoscopy tools.

Advancements in Endoscopic Technology:

The development of high-definition imaging, improved maneuverability of endoscopes, and enhanced precision instruments like single-use biopsy forceps and ergonomic snares is boosting procedural efficiency and safety.

Growth in Minimally Invasive Procedures:

Patients and healthcare providers are increasingly opting for less invasive diagnostic methods. This shift is driving the demand for endoscopic biopsy and polypectomy tools, which offer reduced recovery times and fewer complications.

Restraints:

High Cost of Advanced Devices:

The integration of cutting-edge materials and technologies increases the cost of these instruments, limiting their adoption in cost-sensitive or resource-limited healthcare settings.

Regulatory Hurdles and Reimbursement Issues:

Stringent regulatory requirements for medical devices and inconsistent reimbursement frameworks in various countries can delay market entry and restrict wider adoption.

Opportunity:

Increased Adoption in Ambulatory Surgical Centers (ASCs):

ASCs are rapidly expanding due to their lower operational costs and convenience. This trend presents lucrative opportunities for disposable and reusable endoscopic accessories like forceps, snares, and EUS needles.

Technological Innovations in EUS Needles:

The shift toward fine needle biopsy (FNB) from fine needle aspiration (FNA), along with integration of real-time imaging and molecular diagnostics, opens new frontiers for innovation and market penetration.

Market by System Type Insights:

Among the key device categories, biopsy forceps held the largest market share in 2023. Their widespread use in routine diagnostic endoscopy procedures makes them indispensable tools. However, the EUS needles segment is expected to register the fastest growth due to their critical role in advanced cancer diagnostics and interventional procedures such as drainage and ablation.

Market by End-use Insights:

Hospitals emerged as the dominant end-user segment in 2023, accounting for more than 45% of the total market share. This is attributed to their high patient volume, access to advanced endoscopic infrastructure, and availability of trained specialists. Ambulatory Surgical Centers are anticipated to exhibit the fastest growth owing to shorter wait times, lower costs, and an increasing number of outpatient endoscopic interventions.

Market by Regional Insights:

North America led the market in 2023, driven by its advanced healthcare infrastructure, high awareness of colorectal screening programs, and robust adoption of endoscopic technologies. Meanwhile, Asia-Pacific is poised to grow at the highest CAGR during the forecast period due to improving healthcare access, growing medical tourism, and rising GI disease burden in countries such as China and India.

Competitive Scenario:

Key players in this market include Boston Scientific Corporation, Olympus Corporation, Cook Medical, Medtronic plc, CONMED Corporation, FUJIFILM Holdings Corporation, and Steris plc. These companies are actively investing in product innovation, expanding their geographic footprint, and forming strategic alliances to strengthen their market presence.

Key Developments:

In 2023, Boston Scientific launched a new generation of disposable biopsy forceps designed to reduce cross-contamination risks.

In 2024, Olympus introduced an ergonomic polypectomy snare with enhanced precision control for complex resections.

In 2025, Medtronic announced a partnership with an AI imaging firm to integrate diagnostic decision support into their EUS platform.

Scope of Work – Global Biopsy Forceps, Polypectomy Snares and EUS Needles Market

Report Metric Details

Market Size (2023) USD 1.2 billion

Projected Market Size (2031) USD 2.1 billion

CAGR (2023–2031) 7.2%

Market Segments By System Type (Biopsy Forceps, Polypectomy Snares, EUS Needles); By End-use (Hospitals, Ambulatory Surgical Centers, Specialty Clinics); By Region

Growth Drivers Rising GI disease prevalence, Technological advancements, Surge in minimally invasive procedures

Opportunities Growth of ASCs, Innovation in EUS needle technologies

FAQs:

1. What is the